Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more
Medeon Biodesign - Asset Resilience Ratio
Medeon Biodesign (6499) has an Asset Resilience Ratio of 7.38% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Medeon Biodesign's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Medeon Biodesign's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$104.62 Million | 7.38% |
| Total Liquid Assets | NT$104.62 Million | 7.38% |
Asset Resilience Insights
- Limited Liquidity: Medeon Biodesign maintains only 7.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medeon Biodesign Industry Peers by Asset Resilience Ratio
Compare Medeon Biodesign's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for Medeon Biodesign (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Medeon Biodesign.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.95% | NT$693.84 Million | NT$1.88 Billion | +4.04pp |
| 2023-12-31 | 32.91% | NT$904.03 Million | NT$2.75 Billion | +6.59pp |
| 2022-12-31 | 26.32% | NT$1.06 Billion | NT$4.04 Billion | -10.67pp |
| 2021-12-31 | 36.99% | NT$1.61 Billion | NT$4.36 Billion | +5.07pp |
| 2020-12-31 | 31.92% | NT$1.06 Billion | NT$3.31 Billion | -20.85pp |
| 2019-12-31 | 52.77% | NT$1.33 Billion | NT$2.52 Billion | -1.65pp |
| 2018-12-31 | 54.42% | NT$1.06 Billion | NT$1.95 Billion | +5.56pp |
| 2017-12-31 | 48.86% | NT$800.44 Million | NT$1.64 Billion | -- |